Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
540 A novel antibody that induces PD-L1 degradation results in enhanced tumor responses in a humanized PD-L1 breast carcinoma mouse model compared to Atezolizumab
Compose a Response to This Article
Other responses
No responses have been published for this article.
